Article Text
Statistics from Altmetric.com
Etanercept is a relatively new anti-tumour necrosis factor α (TNF-α) therapy for inflammatory arthritides. Although there may be an association with uveitis,1 there have been no reports of patients experiencing visual disturbance.2 We present a case of a patient who developed symptomatic bilateral peripheral visual field loss shortly after initiation of treatment with etanercept.
Case report
A 59 year old woman was referred complaining of bilateral, sequential peripheral visual field disturbance, which developed during a course of etanercept therapy for rheumatoid arthritis. Initially she noticed a left upper temporal field defect occurring the day after receiving the first injection of etanercept. Following the second injection she became aware of …